Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review

Katja C. Heinz, Charlotte Beaudart, Damon Willems, Isabell Wiethoff, Mickaël Hiligsmann

Résultats de recherche: Contribution à un journal/une revueArticle de revueRevue par des pairs

25 Téléchargements (Pure)

Résumé

Background: Numerous therapies have recently emerged for treatment of patients with atopic dermatitis (AD), a common skin disease, and understanding their cost-effectiveness is of high importance for policy makers. This systematic literature review (SLR) aimed to provide an overview of full economic evaluations that assessed cost-effectiveness of emerging AD treatments. Methods: The SLR was conducted in Medline, Embase, UK National Health Service Economic Evaluation Database and EconLit. Reports published by the National Institute for Health and Care Excellence, the Institute for Clinical and Economic Review and the Canadian Agency for Drugs and Technologies in Health were manually searched. Economic evaluations published from 2017 to September 2022 that compared emerging AD treatments with any comparator were included. Quality assessment was conducted by using the Consensus on Health Economic Criteria list. Results: A total of 1333 references were screened after removing duplicates. Among those references, 15 that conducted a total of 24 comparisons were included. Most studies were from the USA, UK or Canada. Seven different emerging treatments were compared, mostly with usual care. In 15 comparisons (63%), the emerging treatment was cost-effective, and 11 out of 14 dupilumab comparisons (79%) reported that dupilumab was cost-effective. Upadacitinib was the only emerging therapy that was never classified as cost-effective. On average, 13 out of 19 quality criteria (68%) per reference were rated as fulfilled while manuscripts and health technology reports received generally higher quality assessment scores than published abstracts. Discussion: This study revealed some discrepancies in the cost-effectiveness of emerging therapies for AD. A variety of designs and guidelines made comparison difficult. Therefore, we recommend that future economic evaluations use more similar modelling approaches to improve comparability of results. Others: The protocol was published in PROSPERO (ID: CRD42022343993).

langue originaleAnglais
Pages (de - à)1415-1435
Nombre de pages21
journalPharmacoEconomics
Volume41
Numéro de publication11
Les DOIs
Etat de la publicationPublié - nov. 2023
Modification externeOui

Empreinte digitale

Examiner les sujets de recherche de « Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation